

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

Art Unit: 1642

Hohneker, John Arthur et al.

Examiner: Fetterolf, Brandon J

INTERNATIONAL APPLICATION NO: PCT/EP03/05988

FILED: June 06, 2003

U.S. APPLICATION NO: 10/517074

35 USC §371 DATE: April 19, 2005

FOR: Combinations Comprising Epothilones and Pharmaceutical Uses  
Thereof

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed:

☒ supplemental to the Information Disclosure Statement filed September 1, 2005.

If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134 in the name of Novartis.

☒ This Information Disclosure Statement is being filed in accordance with 37 C.F.R. §1.97(c) or 37 C.F.R. §1.97(d).

☒ A letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.


☒ The listed references were cited in the international stage search report and copies are enclosed herewith except for the US patents/applications.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Novartis Pharmaceuticals Corporation  
One Health Plaza, Bldg. 101  
East Hanover, NJ 07936  
(862) 778-7824

Date: 6/3/10

Respectfully submitted,



George Dohmann  
Attorney for Applicant  
Reg. No. 33,593